TY - JOUR
T1 - Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis
T2 - an international analysis
AU - Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer
AU - Metcalfe, Kelly A.
AU - Price, Melanie A.
AU - Mansfield, Carol
AU - Hallett, David C.
AU - Lindeman, Geoffrey J.
AU - Fairchild, Angie
AU - Posner, Joshua
AU - Friedman, Sue
AU - Snyder, Carrie
AU - Lynch, Henry T.
AU - Evans, D. Gareth
AU - Narod, Steven A.
AU - Liede, Alexander
N1 - Funding Information:
Funding information RTI Health Solutions received funding from Amgen Inc. (Thousand Oaks, CA, USA) for this study (study no. 20140153). This publication was also supported by revenue from Nebraska’s excise tax on cigarettes awarded to Creighton University through the Nebraska Department of Health & Human Services (DHHS). Its contents represent the views of the authors and do not necessarily represent the official views of the State of Nebraska or DHHS. Funding was also received from the Liz’s Legacy fund through Kicks for a Cure. Dr. H.T.L.’s work was partially funded through the Charles F. and Mary C. Heider Chair in Cancer Research, which he held at Creighton University. D.G.E. is supported by the all Manchester NIHR Biomedical Research Centre (IS-BRC-1215-20007).
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Cancer Research UK.
PY - 2020/7/21
Y1 - 2020/7/21
N2 - Background: Women with a BRCA1 or BRCA2 mutation have high lifetime risks of developing breast and ovarian cancers. We sought to estimate the prevalence of cancer-related distress and to identify predictors of distress in an international sample of unaffected women with a BRCA mutation. Methods: Women with a BRCA1/2 mutation and no previous cancer diagnosis were recruited from the United States, Canada, the United Kingdom, Australia and from a national advocacy group. Using an online survey, we asked about cancer risk reduction options and screening, and we measured cancer-related distress using the Impact of Event Scale. Results: Among 576 respondents, mean age was 40.8 years (SD = 8.1). On average 4.9 years after a positive test result, 16.3% of women reported moderate-to-severe cancer-related distress. Women who had undergone risk-reducing breast and ovarian surgery were less likely to have (moderate or severe) cancer-related distress compared to other women (22.0% versus 11.4%, P value = 0.007). Women recruited from the advocacy group were more likely to have cancer-related distress than other women (21.6% versus 5.3%, P value = 0.002). Conclusions: Approximately 16% of women with a BRCA1 or BRCA2 mutation experience distress levels comparable to those of women after a cancer diagnosis. Distress was lower for women who had risk-reducing surgery.
AB - Background: Women with a BRCA1 or BRCA2 mutation have high lifetime risks of developing breast and ovarian cancers. We sought to estimate the prevalence of cancer-related distress and to identify predictors of distress in an international sample of unaffected women with a BRCA mutation. Methods: Women with a BRCA1/2 mutation and no previous cancer diagnosis were recruited from the United States, Canada, the United Kingdom, Australia and from a national advocacy group. Using an online survey, we asked about cancer risk reduction options and screening, and we measured cancer-related distress using the Impact of Event Scale. Results: Among 576 respondents, mean age was 40.8 years (SD = 8.1). On average 4.9 years after a positive test result, 16.3% of women reported moderate-to-severe cancer-related distress. Women who had undergone risk-reducing breast and ovarian surgery were less likely to have (moderate or severe) cancer-related distress compared to other women (22.0% versus 11.4%, P value = 0.007). Women recruited from the advocacy group were more likely to have cancer-related distress than other women (21.6% versus 5.3%, P value = 0.002). Conclusions: Approximately 16% of women with a BRCA1 or BRCA2 mutation experience distress levels comparable to those of women after a cancer diagnosis. Distress was lower for women who had risk-reducing surgery.
UR - http://www.scopus.com/inward/record.url?scp=85084502331&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084502331&partnerID=8YFLogxK
U2 - 10.1038/s41416-020-0861-3
DO - 10.1038/s41416-020-0861-3
M3 - Article
C2 - 32393849
AN - SCOPUS:85084502331
VL - 123
SP - 268
EP - 274
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 2
ER -